Part-I- Balance Sheet

(All amounts in Indian Rupees unless otherwise stated)

		As at 31.03	3.2025	As at 31.03.2024		
PARTICULARS	Note	Unaudi	ted	Unaudited		
		INR	MYR	INR	MYR	
ASSETS						
Non-Current Assets						
a) Property, Plant and Equipment		-	-	-	-	
b) Financial Assets						
i)Others		-	-	-	-	
		-	-	-	-	
Current Assets						
a) Financial Assets						
i)Cash and Cash Equivalents	1	532,362	27,621	24,419	1,385	
ii)Trade Receivable		-	-	82,581,257	4,683,893	
b) Other Current Assets	2	-	-	-	-	
.,		532,362	27,621	82,605,676	4,685,278	
		, <u> </u>	<i>'</i>	, ,	• •	
TOTAL		532,362	27,621	82,605,676	4,685,278	
EQUITY AND LIABILITIES			·			
Equity						
a) Equity Share capital	3	481,853	25,000	440,773	25,000	
b) Other Equity	4	(62,248)	(3,230)	(35,801,813)	(2,030,629)	
		419,605	21,770	(35,361,041)	(2,005,629)	
LIABILITIES						
Non-Current liabilities						
a) Financial Liabilities						
i) Borrowings	5	-	-	94,076,017	5,335,860	
ii) Other Financial Liabilities	6	-	-	22,094,992	1,253,197	
Current liabilities						
a) Financial Liabilities						
i) Other Financial Liabilities	7	112,757	5,850	1,795,707	101,850	
		112,757	5,850	117,966,717	6,690,907	
TOTAL		532,362	27,621	82,605,676	4,685,278	

For and on behalf of the board of Directors of Indo Biotech SDN. BHD

Sd/ Ramakant Innani Director

Part - II - Statement of Profit and Loss

(All amounts in Indian Rupees unless otherwise stated)

Particulars	Note	For the period ended 31.03.2025 Unaudited		For the peri 31.03.2	
Particulars	Note			Unaudited	
		INR	MYR	INR	MYR
Revenue Revenue from operations		-	-	-	-
Revenue from Operations		1 025 701	-	-	-
Other income Total Revenue	8	1,835,791 1,835,791	100,000 100,000	-	-
Total Nevenue		1,033,771	100,000		
Expenses a) Employee benefits expense b) Finance costs c) Depreciation and amortisation expense	9 10	- 5,481,189 -	- 298,574 -	326,705 7,775,549	18,000 428,399
d) Other expenses	11	(604,034)	(32,903)	11,513,248	634,330
Total Expenses		4,877,155	265,670	19,615,502	1,080,728
Profit / (Loss) before exceptional items and tax Exceptional items (Income)/Expenses Profit / (Loss) before tax Tax expense a.Current tax	12	(3,041,363) (40260184) 37,218,821	(165,670) (2193070) 2,027,399	(19,615,502) (19,615,502)	(1,080,728) (1,080,728)
b.Deferred tax (Net)					
		-	-	-	-
Profit / (Loss) for the year Other comprehensive Income		37,218,821	2,027,399	(19,615,502)	(1,080,728)
Total Comprehensive Income		37,218,821	2,027,399	(19,615,502)	(1,080,728)
Earning per equity share of face value of MR 1 (for continuing operations) Basic Diluted		372,188 372,188	20,274 20,274	(196,155) (196,155)	(10,807) (10,807)
Weighted Average No of shares used in computing earnings per share Basic Diluted		100 100	100 100	100 100	100 100

For and on behalf of the board of Directors of Indo Biotech SDN. BHD

Sd/ Ramakant Innani Director

(All amount are in Indian Rupees unless otherwise stated)

1 Cash and cash equivalents

Particulars	As at 31.	03.2025	As at 31.03.2024	
	INR	MYR	INR	MYR
a) Balance with banks				
- In Current Accounts	532,362	27,621	24,419	1,385
TOTAL	532,362	27,621	24,419	1,385

2 Other Current Assets

Particulars	As at 31.0	03.2025	As at 31.03.2024	
	INR	MYR	INR	MYR
Unsesured (Considering Good)				
Other Receivables	10,720,062	556,190	9,806,130	556,190
	10,720,062	556,190	9,806,130	556,190
Doubtful	-	-	-	-
	10,720,062	556,190	9,806,130	556,190
Less: Provision for doubtful advances	(10,720,062)	(556,190)	(9,806,130)	(556,190)
TOTAL	-	-	-	-

3 **Equity Share Capital**

Particulars	As at 31.	03.2025	As at 31.03.2024	
	INR	MYR	INR	MYR
Issued,Subscribed and fully Paid up 25000 Common Shares, RM 1/- each par value	481,853	25,000	440,773	25,000
TOTAL	481,853	25,000	440,773	25,000

4 Other Equity

Particulars	As at 31.0	As at 31.03.2025		03.2024
Particulars	INR	MYR	INR	MYR
Balance at the beginning of the Reporting period	(36,694,654)	(2,030,629)	(17,079,152)	(949,901)
Add: Total Comprehensive Income for the Year	37,218,821	2,027,399	(19,615,502)	(1,080,728)
	524,166	(3,230)	(36,694,654)	(2,030,629)
Foreign Currency Transalation Reserve	(586,414)	•	892,841	-
Balance at the end of the Reporting period	(62,248)	(3,230)	(35,801,813)	(2,030,629)

5 Long-term borrowings

Particulars	As at 31.	03.2025	As at 31.03.2024	
	INR	MYR	INR	MYR
Unsecured Loan - From Shilpa Medicare Limited	-	-	94,076,017	5,335,860
TOTAL	-	-	94,076,017	5,335,860

(All amount are in Indian Rupees unless otherwise stated)

6 Other Financial Liabilities - Non Current

Particulars	As at 31.	03.2025	As at 31.03.2024	
	INR	MYR	INR	MYR
Interest accrued but not due on Borrowings	-	-	22,094,992	1,253,197
TOTAL	-	-	22,094,992	1,253,197

7 Other Financial Liabilities - Current

Particulars	As at 31.	03.2025	As at 31.03.2024	
	INR	MYR	INR	MYR
Accounts Payable	112,757	5,850	1,795,707	101,850
TOTAL	112,757	5,850	1,795,707	101,850

8 Other Income

Particulars	As at 31.	As at 31.03.2025		.03.2024
	INR	MYR	INR	MYR
Other Income	1,835,791	100,000	-	-
TOTAL	1,835,791	100,000	-	-

9 Employee Benefits Expense

Particulars	-	For the period ended 31.03.2025		For the period ended 31.03.2024	
	INR	MYR	INR	MYR	
Salaries & Wages	-	-	326,705	18,000	
TOTAL	-	-	326,705	18,000	

10 Finance Cost

Particulars	For the period ended 31.03.2025		For the period ended 31.03.2024	
	INR	MYR	INR	MYR
Interest on Loan from Shilpa Medicare Limited	5,481,189	298,574	7,775,549	428,399
TOTAL	5,481,189	298,574	7,775,549	428,399

11 Other Expenses

Particulars	For the period ended 31.03.2025		For the period ended 31.03.2024	
	INR	MYR	INR	MYR
Rent Expense	-	-	108,902	6,000
Exchange loss /(gain) net	(677,465)	(36,903)	1,073,399	59,140
Other Expenses	73,432	4,000	235,953	13,000
TOTAL	(604,034)	(32,903)	11,513,248	634,330

12 Exceptional (Income)/Expenses

Particulars	For the period ended 31.03.2025		For the period ended 31.03.2024	
	INR	MYR	INR	MYR
Unsecured Long Term Loan- SML	(13,185,920)	(718,269)	-	-
Interest on Unsecured long term loan-SML	(27,074,264)	(1,474,801)	-	-
TOTAL	(40,260,184)	(2,193,070)	-	-